ClinicalTrials.gg
RecruitingNCT07507422PERSISTUpdated Nov 5, 2026

Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation Therapy

An observational study in Chronic Pain and Intractable Pain, sponsored by Medtronic. Recruiting at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Medtronic · Observational

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 5, 2026First site in Switzerland5 sites added+1 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
970
Ages
18 Years and older
Sex
All
01

Study summary

The PERSIST study is being conducted within Medtronic's active post-market surveillance platform, the Product Surveillance Registry (PSR). The purpose of PERSIST is to generate long-term evidence for the Inceptiv™ Spinal Cord Stimulation therapy.

02

Conditions studied

  • Chronic Pain
  • Intractable Pain
03

In context

Chronic Pain

3,227 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

This study's planned enrollment of 970 is above the median of 120 across 753 observational studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

Medtronic is the lead sponsor of 42 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The intended study population is adults with chronic, intractable pain of the trunk and/or limbs indicated for a Medtronic Inceptiv™ implantable neurostimulation system. Study eligibility criteria must be met to participate in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older
  2. Patient must be SCS therapy naïve
  3. A clinical decision was made for the patient to receive an Inceptiv™ SCS system (pending satisfactory results from a Medtronic SCS trial) limited to on-label leads based on the specific geography for an on-label indication prior to enrollment in the study.
  4. Patient is on stable opioid dosage for 3 months prior to enrollment, if applicable
  5. Pain intensity of ≥ 6 as measured using the NPRS (0-10) in the predominant area(s) of pain that SCS is intended to treat
  6. Patient must have an on-label indication specific to geography.

    • NOTE: Patients may be enrolled if they have upper limb radicular limb pain, related or unrelated to spine surgery
    • NOTE: In the US, patients experiencing chronic back pain without a history of spine surgery and not eligible for spine surgery are on-label candidates for SCS if the pain is associated with degenerative disc disease, herniated disc, or radicular pain syndrome. Radicular pain syndrome (with or without prior spine surgery) is an approved indication for SCS implant.
  7. Diagnosis of chronic back and/or limb pain for an on-label indication lasting at least six months.

Exclusion criteria

Exclusion Criteria:

  1. Has any existing or is planning to have a new active implantable neuromodulation device or system during the 5 year follow up period (e.g., peripheral nerve stimulation, sacral neuromodulation, intrathecal drug delivery system, a second SCS system)
  2. Has a complex pain pattern that involves both upper and lower limbs or back and upper limb
  3. Has a planned major medical procedure within 6 months before enrollment or after implant that may interfere with study results or confound results as determined by the Investigator
  4. Has a planned interventional procedure within 6 weeks (+/- 2 weeks) before enrollment or after implant that may interfere with study results or confound results as determined by the Investigator
  5. Major untreated or unstable psychiatric comorbidity, such as suicidal ideations, personality disorders, schizophrenia etc., that could interfere with accurate pain reporting, study procedures, and/or confound evaluation of study, as determined by the Investigator
  6. Subjects with PCS total score >30 are not eligible unless ALL of the following are met:

    1. Absence of uncontrolled major psychiatric disorder or active suicidality based on clinical evaluation.
    2. Investigator documentation of adequate understanding of therapy, realistic expectations, and anticipated compliance with protocol follow-up
  7. Major non-indicated, untreated or progressive disease (e.g., neurodegenerative disease {not including Diabetic Peripheral Neuropathy}, heart failure, cancer, osteoarthritis, fibromyalgia, chronic fatigue syndrome), or injury (e.g., fall resulting in hip fracture) that could interfere with accurate pain reporting, study procedures, and/or confound evaluation of study as determined by the Investigator
  8. Has inpatient or outpatient admissions for drug or alcohol dependency within past 12 months or current/ongoing substance abuse
  9. Has a current prescription of ≥90 morphine milligram equivalents (MME) per day
  10. Has predominant mechanical back pain arising from facet or sacroiliac joint pain as the main cause of chronic low-back pain if low-back pain is the predominant pain condition, as determined by the Investigator
  11. Has mechanical spine instability (eg. Spondylolisthesis grade 2) as determined by the Investigator
  12. Has an active systemic or local infection that would delay trial or implant
  13. Is pregnant or planning on becoming pregnant
  14. Has a of less than 1 year
  15. Involved in an injury claim, under current litigation, beneficiary of an injury claim, receiving worker's compensation, or planning any future litigation
  16. Has a condition that the Investigator determines would significantly increase perioperative risk (e.g., unstable or severe cardiac disease, liver disease, uncontrolled diabetes, kidney disease)

Patients enrolled into the study with Diabetic Peripheral Neuropathy, Complex Regional Pain Syndrome and Upper Limb pain are required to meet further inclusion/exclusion criteria in order to contribute to the analysis for that particular condition. These criteria are designed to ensure that the patient's condition aligns with the standard diagnostic criteria set by applicable clinical guidelines.

Painful Diabetic Peripheral Neuropathy (DPN) Inclusion Criteria

  • Clinical diagnosis of diabetes mellitus according to the American Diabetes Association guidelines (ADA).
  • Predominant pain condition being treated by SCS is lower-limb pain due to DPN
  • (HbA1c) must be \<8% within 6 months of enrollment for inclusion or have completed a preoperative risk assessment if >8%
  • Presence of either numbness or at least one sensory disturbance (e.g., increased or decreased sensitivity, burning, pricking/stabbing, aching, "pins and needle" sensation) in the foot/feet.

Painful DPN Exclusion Criteria

  • Lower-limb pain not associated with DPN or that cannot be distinguished from DPN (e.g., mononeuropathies, proximal neuropathies, nonneuropathic pain, peripheral vascular disease)
  • History of lower-limb amputation or planned lower-limb amputations due to diabetes
  • Large (≥3cm) and/or gangrenous ulcers or active infection of the lower limbs

Complex Regional Pain Syndrome (CRPS) Inclusion Criteria

  • Meets diagnostic criteria for CRPS (International Association for the Study of Pain "Budapest Criteria")
  • Disease that is clinically restricted to one hand or foot and affects the entire hand, foot or lower extremity
  • CRPS is the predominant pain condition that SCS is intended to treat

CRPS Exclusion Criteria

  • Presence of Reynaud's disease
  • Current or previous neurologic abnormalities unrelated to CRPS
  • Another condition affecting the function of the diseased or contralateral extremity
  • Dystonia as a predominant component of their presentation

Upper Limb Pain (ULP) - non CRPS Inclusion Criteria

  • Be diagnosed with radicular pain syndrome, or be diagnosed with radicular pain secondary to failed back surgery or herniated disk

ULP - non CRPS Exclusion Criteria

  • Has significant cervical stenosis, as determined by the Investigator
  • Failed treatments of carpal tunnel syndrome and/or cubital tunnel syndrome
  • Has mechanical neck pain (e.g., facet spondylosis), as determined by the Investigator
  • Any previous history of surgery on the posterior elements (laminectomy, posterior fusion) of the cervical spine
  • Has brachial plexus injury as predominant cause of pain
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
970 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • PERSIST Cohort

    Device: Commercially available Inceptiv™ neurostimulation systems

Interventions

  • DeviceCommercially available Inceptiv™ neurostimulation systems

    Spinal cord stimulation therapy delivered during trialing and following implant of commercially available Inceptiv™ neurostimulation systems

06

What researchers measure

Primary outcomes

  1. Percentage of implanted patients who have a ≥ 50% improvement in pain score as assessed by numeric pain rating scale (NPRS) from baseline for the predominant pain being treated at 6 months following device activation

    This outcome measures the percentage of implanted patients who demonstrate improvement in pain for the predominant pain condition being treated at 6 months following device activation, compared to baseline. Pain is assessed using the NPRS (with 0=no pain and 10=highest level of pain).

    Time frame: Baseline and 6 months after device activation

  2. Percentage of implanted patients who are a composite responder at 6 months following device activation

    A composite responder is defined as an implanted patient who demonstrates an improvement from baseline in at least one of the following measures at the specified follow-up time: pain, quality of life, or pain-related disability. Pain is assessed using the Numeric Pain Rating Scale (NPRS 0=no pain and 10=worst possible pain), with improvement defined as a reduction in pain score from baseline. Quality of life is assessed using the EQ-5D-5L index value, with improvement defined as positive change from baseline. Pain-related disability is assessed using the Pain Disability Index (PDI), with improvement defined as negative change from baseline.

    Time frame: Baseline and 6 months after device activation

Secondary outcomes

  1. Percentage of implanted patients who are a composite responder

    A composite responder is defined as an implanted patient who demonstrates an improvement from baseline in at least one of the following measures at the specified follow-up time: pain, quality of life, or pain-related disability. Pain is assessed using the Numeric Pain Rating Scale (NPRS 0=no pain and 10=worst possible pain), with improvement defined as a reduction in pain score from baseline. Quality of life is assessed using the EQ-5D-5L index value, with improvement defined as positive change from baseline. Pain-related disability is assessed using the Pain Disability Index (PDI), with improvement defined as negative change from baseline.

    Time frame: Baseline and 3 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months, 60 months after device activation

07

Study locations

10 of 10 sites recruiting
  • Center for Pain and Supportive Care
    Phoenix, Arizona 85028, United States
    Recruiting
    • Krisstin Hammond · Contact
    • Gobi Paramanandam · Principal investigator
  • Relieve Pain Center
    San Diego, California 92110, United States
    Recruiting
  • Innovative Pain Treatment Solutions
    Temecula, California 92590-4801, United States
    Recruiting
  • Christian Hospital
    St Louis, Missouri 63136-6119, United States
    Recruiting
    • Maksim Shoykhet · Contact
    • Christopher Beuer · Principal investigator
  • 5500 Reno Corporate Dr Ste 300
    Reno, Nevada 89511, United States
    Recruiting
    • Cara Davis · Contactdavis@rtpain.com · (775) 276-8398
    • Ali Nairizi · Principal investigator
  • Pain Diagnostics and Interventional Care
    Sewickley, Pennsylvania 15143-1300, United States
    Recruiting
  • North Texas Orthopedics and Spine Center
    Houston, Texas 76051-3930, United States
    Recruiting
    • Katelynn Traver · Contact
    • Melissa Murphy · Principal investigator
  • Christus Surgery Center- Westover Hills, LLC
    San Antonio, Texas 78251, United States
    Recruiting
  • Hôpital Claude Huriez
    Lille, 59037, France
    Recruiting
  • Hopital de La Tour Clinique de la Douleur
    Meyrin, 1217, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Sites
5 sites added, 1 site removed — first site in Switzerland
Show 5 added (3 United States, 1 France, 1 Switzerland)
  • Innovative Pain Treatment Solutions · Temecula, United States
  • 5500 Reno Corporate Dr Ste 300 · Reno, United States
  • Pain Diagnostics and Interventional Care · Sewickley, United States
  • Hôpital Claude Huriez · Lille, France
  • Hopital de La Tour Clinique de la Douleur · Meyrin, Switzerland
Show 1 removed
  • Hôpital Claude Huriez · Lille, France
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    5 sites added, 1 site removed — first site in Switzerland
    Show 5 added (3 United States, 1 France, 1 Switzerland)
    • Innovative Pain Treatment Solutions · Temecula, United States
    • 5500 Reno Corporate Dr Ste 300 · Reno, United States
    • Pain Diagnostics and Interventional Care · Sewickley, United States
    • Hôpital Claude Huriez · Lille, France
    • Hopital de La Tour Clinique de la Douleur · Meyrin, Switzerland
    Show 1 removed
    • Hôpital Claude Huriez · Lille, France

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07507422
Lead sponsor
Medtronic
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Apr 17, 2026
Primary completion
Jun 27, 2029 (estimated)
Completion
Jan 11, 2034 (estimated)
Last update
Nov 5, 2026

Study contacts

Study Inbox
Contact
rs.persiststudy@medtronic.com
1-800-633-8766
Holly Norman, PhD, MBA
study director · Medtronic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion